Malin (MLLNF) Other Long-Term Liabilities: $4.50 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLNF Malin Corporation PLC MLLNF
17 GF Score
Price $6.40
View Full Analysis

What is Malin Other Long-Term Liabilities?

Malin MLLNF 17 Other Long-Term Liabilities is $4.50 Mil as of Dec. 2024. GuruFocus rates MLLNF with a GF Score™ of 17/100.

Malin's other long-term liabilities for the quarter that ended in Dec. 2024 was $4.50 Mil.

Malin's quarterly other long-term liabilities increased from Dec. 2023 ($6.65 Mil) to Jun. 2024 ($10.44 Mil) but then declined from Jun. 2024 ($10.44 Mil) to Dec. 2024 ($4.50 Mil).

Malin's annual other long-term liabilities increased from Dec. 2022 ($4.45 Mil) to Dec. 2023 ($6.65 Mil) but then declined from Dec. 2023 ($6.65 Mil) to Dec. 2024 ($4.50 Mil).

Malin Other Long-Term Liabilities Related Terms

Malin Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Malin's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malin Other Long-Term Liabilities Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.96 7.57 4.45 6.65 4.50

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.45 5.09 6.65 10.44 4.50
MLLNF
17GF Score
Malin Corporation PLC MLLNF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malin Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $4.50 Mil mean?
Malin (MLLNF) has a Other Long-Term Liabilities of $4.50 Mil as of Dec. 2024. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Malin and its competitors.
Is Malin's Other Long-Term Liabilities too high?
Malin's current Other Long-Term Liabilities is $4.50 Mil. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's Other Long-Term Liabilities compare to ZTS and UTHR?
Malin's Other Long-Term Liabilities of $4.50 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Malin and its competitors. Malin's current Other Long-Term Liabilities is $4.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current Other Long-Term Liabilities of $4.50 Mil. The current Other Long-Term Liabilities is $4.50 Mil. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Malin (MLLNF), the current Other Long-Term Liabilities is $4.50 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score

Get the complete analysis for MLLNF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.40
Price